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The purpose of this brief communication is to review
several drugs implicated as nephrotoxins in the recent
literature. This review will not endeavor to provide an
exhaustive review of all nephrotoxins. There are several
excellent and comprehensive reviews of this topic avail-
able [1].
INCIDENCE OF ACUTE RENAL FAILURE
CAUSED BY DRUGS
There is widespread agreement that drug nephrotoxic-
ity plays a major role in the high incidence and prevalence
of acute renal failure in both hospitalized and nonhospi-
talized patients. Recent reviews have suggested that be-
tween 5% and 10% of acute renal failure recognized in
such patients is caused, at least in part, by drugs [2]. An-
tibiotics play a major role in these nephrotoxicities, but
other drugs are clearly implicated in many cases. The inci-
dence of acute renal failure caused by nephrotoxic agents
is particularly notable among the elderly, and there are
several reasons for this: (1) there is an age-related decline
in glomerular filtration rate in older individuals, and this
leads to a decreased clearance of primary drugs or the
metabolites of such drugs; (2) there may be a decrease
in kidney blood flow and an increase in concentration
of some drugs in the cells of medulla; (3) primary dif-
ferences exist between the elderly and nonelderly and
pharmacokinetics of drugs. For example, there may be an
increase in free-drug concentration in the elderly in con-
junction with hypoalbuminemia, or because of retained
metabolites [2]; (4) a decrease in total body water may
also alter drug distribution in an adverse way; (5) finally,
there may also be a decrease in hepatic metabolism with
longer half-lives of some drugs. For example, in a recent
study by Dowling et al, individuals with underlying re-
nal disease had a decrease in the maximum cytochrome
P450 enzyme activity inducible by rifampin as compared
to normal controls [3].
With regard to the fate of individuals who develop
acute renal failure caused by nephrotoxicity, several
outcomes have been reported. In most cases, the drug
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nephrotoxicity is partly or wholly reversible. However,
some authors have suggested that as many as 50% to
60% of individuals who suffer such nephrotoxicity may
retain an element of permanent renal damage. One re-
cent report suggested that individuals who have intersti-
tial nephritis with granuloma formation on kidney biopsy
are more vulnerable to developing these chronic kidney
effects [4]. In this report, as many as 50% of subjects
suffering from nephrotoxic acute renal failure suffered
chronic and permanent renal damage from the exposure
[4]. As with all cases of acute renal failure, the mortal-
ity rate is extremely high in hospitalized patients, and
this is particularly true in the setting of the intensive care
unit [5]. Thus, avoiding any decrement in kidney function
caused by drug exposures is a major factor in reducing
overall morbidity.
NEPHROTOXICITY CAUSED BY COX-2
INHIBITORS
The COX-2 drugs act by inhibiting the cyclooxygenase-
2 isoenzyme, which is responsible for prostaglandin syn-
thesis and is constitutive in some tissues. The enzyme
is markedly stimulated by endotoxin, cytokines, and
other growth factors. The well-known acute vasocon-
striction that follows the inhibition of nonconstitutive
prostaglandin synthesis in the kidney by nonselective
cyclooxygenase inhibitors would theoretically be di-
minished by using a selective cyclooxygenase inhibitor.
However, if arachidonate metabolism via COX were
blocked, it might proceed down the lipooxygenase path-
way, which could result in the production of vasoconstric-
tive leukotrienes, thereby leading to renal ischemia [6].
Additionally, COX-2 inhibitors may promote apoptosis
in medullary interstitial cells under conditions of water
deprivation, and this may also favor an acute reduction
in kidney function [7].
There are several recent studies that have sug-
gested that, under conditions of volume challenge,
renal vasoconstriction does occur upon exposure to
cyclooxygenase-2 inhibitors. One of these studies in hu-
mans suggested that there was as much as a 10 mL/minute
decrease in glomerular filtration rate from baseline on
day 6 of exposure to a selective cyclooxygenase inhibitor
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[8]. Thus, the acute effects of exposure to such drugs may
produce a decline in glomerular filtration rate (GFR) un-
der certain circumstances. Other physiologic effects of
the COX-2 isoenzyme in the kidney include inhibition of
renin secretion stimulated via the macula densa [9], an
effect to increase blood pressure in laboratory animals
[10], and an ability to facilitate the natriuretic response
to furosemide in laboratory animals [11]. The array of ef-
fects of inhibition of the COX-2 isoenzyme, then, might
be a decrease in GFR, an increase in blood pressure and
edema, a decrease in sodium excretion in response to
loop diuretics, and hyperkalemia secondary to the an-
tirenin effects of the drugs. The chronic effects of use of
these drugs on kidney function is not known because the
time of exposure to these drugs has been only in recent
years.
Perhaps one of the most illuminating studies per-
formed on the question of how common nephrotoxic-
ity is in the setting of cyclooxygenase-2 inhibitors was
from a study that was not designed to examine this ques-
tion [12]. This study was aimed at learning the effect of
celecoxib (200 mg bid) versus diclofenac and omeprazole
on GI bleeding in arthritis patients; a 6-month follow-up
was done in 2 groups of rheumatoid arthritis patients.
The incidence of GI bleeding in the 2 groups was com-
parable at the end of 6 months. Of interest is the fact
that hypertension, peripheral edema, and renal failure
were noted in 24% of the celecoxib group and 31% of
the diclofenac/omeprazole group. Renal failure was seen
in 5.6% of the 144 celecoxib patients and 6.3% of the
diclofenac plus omeprazole patients. Thus, it is clear that
renal adverse events are common with the use of selective
cyclooxygenase-2 inhibitors over relatively short periods
of time. This leads to the conclusion that, for the time
being, cyclooxygenase-2 inhibitors should not be charac-
terized as “renal-protective.” Cautions that are operant in
the use of nonselective cyclooxygenase inhibitors should
also be applied to these cyclooxygenase-2 inhibitors.
BISPHOSHONATES
The class of drugs known as bisphoshonates has been
extremely useful as chronic therapy for not only hyper-
calcemia, but also in preventing fractures in patients with
metastatic cancer. These drugs reduce morbidity from hy-
percalcemia, and also improve osteoporosis in this patient
population group. The drugs work by binding phosphate
crystals within the bone matrix, thereby disrupting oste-
olytic activity. In addition to being used in hypercalcemic
syndromes in individuals with osteolytic metastases, these
drugs are also useful in Paget’s disease.
With regard to nephrotoxicity, there are a grow-
ing number of case reports of nephrotoxicity follow-
ing use of pamidronate and zoledronate. With regard
to pamidronate, the dose range of 90 to 360 mg/month
for between 15 to 48 months has generated a num-
ber of these case reports. One interesting feature of
pamidronate nephrotoxicity has been that in several in-
dividuals nephrotic syndrome with a collapsing glomeru-
lar sclerosis has been seen on renal biopsy [13]. There
are also tubular atrophy, a loss of the proximal tubule
brush border membrane, and cytoplasmic vacuolization
as common features in this form of nephrotoxicity. Typ-
ically, there is very little complement staining and light
IgM staining on immunofluorescence. Once the drug
is stopped, there is frequently a slow resolution of the
acute renal failure over several months. The mechanism
of this nephrotoxicity is not completely understood, but
involves the transport of pamidronate intracellularly in
podocytes in all likelihood. The intracellular location of
pamidronate inhibits mevalonate pathways and disrupts
GTPase anchoring proteins. This, in turn, impairs cell en-
ergetics and compromises the cell skeleton. Prevention of
pamidronate nephrotoxicity is best achieved by avoiding
greater than 90 mg per month infusions and employing
very slow IV infusions.
With regard to zoledronate, the incidence of acute re-
nal failure has been reported to be in the 9% to 13% range
(when 4 mg IV over 15 minutes every 3 to 4 weeks for
1 year has been given) [14]. The pathology of zoledronate
nephrotoxicity is dominated by a diffuse tubular atrophy
and injury without interstitial nephritis. The excretion of
zoledronate is greater than the GFR, which suggests that
there is active tubular secretion of the drug. The average
time for developing the nephrotoxicity occurs at about
the 5-month mark in most series. There is typically a grad-
ual increase in the serum creatinine concentration, and
slow recovery is expected. The avoidance of nephrotox-
icity is best obtained by giving very slow infusions over
30 minutes to 40 minutes (and not 10 to 15 minutes). Vol-
ume repletion is also recommended before the drug is
started.
INTRAVENOUS IMMUNOGLOBULIN G
Intravenous immunoglobulin G is useful in immuno-
deficiency syndromes where the total dose is 0.6 g/kg. In-
flammatory neurologic conditions and myasthenia gravis
along with blistering skin diseases are other indications
for the drug. The adverse event rate with intravenous im-
munoglobulin G is in the range of 1% to 15%, and there
are approximately 100 cases of transient oliguric acute
renal failure reported with the drug. The renal biopsy
in one of the renal transplant patients who developed
an increase in serum creatinine upon exposure to in-
travenous immunoglobulin G showed osmotic nephro-
sis of the proximal tubules [15]. In this series of 9 cases
of nephrotoxicity following exposure to intravenous im-
munoglobulin G, 7 of the 9 cases showed vacuoliza-
tion and degeneration of proximal convoluted tubule
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cells. The risk factors for developing the intravenous im-
munoglobulin G–associated acute renal failure were a
creatinine concentration of greater than 1.5 mg/dL and
age over 65 years. An underlying paraproteinemia or
paraproteinuria was also a risk factor [15]. Of interest
is the fact that these lesions in the proximal tubule are
identical to those of sucrose nephrotoxicity, which is a
primary vehicle for the drug in many formulations for
the drug. The mechanism of such an effect is uptake of
sucrose (or any other nonmetabolizable substance such as
mannitol or dextran), which leads to an increase in intra-
cellular osmolality and subsequent cell swelling and dam-
age. Sucrose is still used as a solubulizing agent because of
lower cost, but there are other solubulizing agents, such as
amino acids, on the market. Some manufacturers are also
suggesting using a lower concentration of immunoglobu-
lin G, and giving the drug slowly at a dose of 0.4 g/kg over
12 hours in an effort to reduce nephrotoxicity.
CIDOFIVIR AND ADEFOVIR
Cidofivir and adefovir are useful antiviral nucleotide
analogues with activity against DNA viruses. They are
used occasionally in cytomegalovirus (CMV) retinitis and
against other herpes viruses, as well as HIV. Adefovir has
had use in treating hepatitis B infections. With regard
to cidofivir, doses greater than 5 mg/kg have been as-
sociated with acute renal failure. Renal biopsies in such
cases have been characterized by proximal tubular necro-
sis and a dense fibrosis without an interstitial infiltrate.
Other proximal tubular transport defects, such as glyco-
suria [16], have been seen in some patients with cidofivir
nephrotoxicity.
The mechanism of cidofivir nephrotoxicity has been
linked to the human organic anion transporter (hOAT).
This transporter is located on the basal lateral membrane
of the proximal tubule and has a key role in the excretion
of metabolites, toxins, xenobiotics, and other agents with
an anionic charge. The hOAT is key in the removal of
salicylates, urate, and methotrexate from the blood. In
addition, the hOAT also transports nucleotide analogues
into the proximal convoluted tubule. Probenicid reduces
the intracellular accumulation of these drugs by blocking
the hOAT [16]. In one recent study in Chinese hamster
ovary cells, the concentrations of adefovir and cidofovir
were dramatically increased in those cells with the organic
anion transporter present; the magnitude of the increase
was several hundred-fold [16].
Nephrotoxicity from these 2 agents can be reduced by
using probenicid at 3 g p.o. 3 hours before the dose, 2 g of
probenicid 2 hours after the dose, and 1 g of probenicid
8 hours after the dose. Predose volume expansion and
adequate hydration are recommended. The drug should
be avoided, if at all possible, in patients with baseline
serum creatinine concentrations greater than 1.5 mg/dL.
One clue to the presence of adefovir toxicity is the pres-
ence of the Fanconi syndrome, with phosphaturia and
hypophosphatemia reported.
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